Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
Int J Mol Sci ; 22(8)2021 Apr 11.
Article in English | MEDLINE | ID: mdl-33920464

ABSTRACT

Salmon calcitonin is a good model for studying amyloid behavior and neurotoxicity. Its slow aggregation rate allows the purification of low molecular weight prefibrillar oligomers, which are the most toxic species. It has been proposed that these species may cause amyloid pore formation in neuronal membranes through contact with negatively charged sialic acid residues of the ganglioside GM1. In particular, it has been proposed that an electrostatic interaction may be responsible for the initial contact between prefibrillar oligomers and GM1 contained in lipid rafts. Based on this evidence, the aim of our work was to investigate whether the neurotoxic action induced by calcitonin prefibrillar oligomers could be counteracted by treatment with neuraminidase, an enzyme that removes sialic acid residues from gangliosides. Therefore, we studied cell viability in HT22 cell lines and evaluated the effects on synaptic transmission and long-term potentiation by in vitro extracellular recordings in mouse hippocampal slices. Our results showed that treatment with neuraminidase alters the surface charges of lipid rafts, preventing interaction between the calcitonin prefibrillar oligomers and GM1, and suggesting that the enzyme, depending on the concentration used, may have a partial or total protective action in terms of cell survival and modulation of synaptic transmission.


Subject(s)
Amyloid Neuropathies , Calcitonin/toxicity , Fish Proteins/toxicity , Neuraminidase/pharmacology , Salmon , Amyloid Neuropathies/chemically induced , Amyloid Neuropathies/metabolism , Amyloid Neuropathies/pathology , Amyloid Neuropathies/prevention & control , Animals , G(M1) Ganglioside/metabolism , Male , Membrane Microdomains/metabolism , Membrane Microdomains/pathology , Mice , Mice, Inbred BALB C , Static Electricity
2.
Neurochem Res ; 40(11): 2365-73, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26441223

ABSTRACT

Accumulated soluble amyloid ß (Aß)-induced aberrant neuronal network activity has been recognized as a key causative factor leading to cognitive deficits which are the most outstanding characteristic of Alzheimer's disease (AD). As an important structure associated with learning and memory, the hippocampus is one of the brain regions that are impaired very early in AD, and the hippocampal CA1 region is selectively vulnerable to soluble Aß oligomers. Our recent study showed that soluble Aß1-42 oligomers induced hyperactivity and perturbed the firing patterns in hippocampal neurons. Rhynchophylline (RIN) is an important active tetracyclic oxindole alkaloid isolated from Uncaria rhynchophylla which is a traditional Chinese medicine and often used to treat central nervous system illnesses such as hypertension, convulsions, tremor, stroke etc. Previous evidence showed that RIN possessed neuroprotective effects of improving the cognitive function of mice with Alzheimer-like symptoms. In the present study, we aimed to investigate the protective effect of RIN against soluble Aß1-42 oligomers-induced hippocampal hyperactivity. The results showed that (1) the mean frequency of spontaneous discharge was increased by the local application of 3 µM soluble Aß1-42 oligomers; (2) 30 µM RIN did not exert any obvious effects on basal physiological discharges; and (3) treatment with RIN effectively inhibited the soluble Aß1-42 oligomers-induced enhancement of spontaneous discharge, in a concentration-dependent manner with an IC50 = 9.0 µM. These in vivo electrophysiological results indicate that RIN can remold the spontaneous discharges disturbed by Aß and counteract the deleterious effect of Aß1-42 on neural circuit. The experimental findings provide further evidence to affirm the potential of RIN as a worthy candidate for further development into a therapeutic agent for AD.


Subject(s)
Amyloid Neuropathies/prevention & control , Amyloid Neuropathies/physiopathology , Amyloid beta-Peptides/antagonists & inhibitors , Amyloid beta-Peptides/toxicity , CA1 Region, Hippocampal/drug effects , CA1 Region, Hippocampal/physiopathology , Indole Alkaloids/pharmacology , Neuroprotective Agents/pharmacology , Amyloid Neuropathies/psychology , Animals , Cognition Disorders/chemically induced , Cognition Disorders/psychology , Dose-Response Relationship, Drug , Male , Oxindoles , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/toxicity , Rats , Rats, Sprague-Dawley , Uncaria/chemistry
3.
Proc Natl Acad Sci U S A ; 107(17): 7710-5, 2010 Apr 27.
Article in English | MEDLINE | ID: mdl-20385841

ABSTRACT

Protein misfolding and formation of beta-sheet-rich amyloid fibrils or aggregates is related to cellular toxicity and decay in various human disorders including Alzheimer's and Parkinson's disease. Recently, we demonstrated that the polyphenol (-)-epi-gallocatechine gallate (EGCG) inhibits alpha-synuclein and amyloid-beta fibrillogenesis. It associates with natively unfolded polypeptides and promotes the self-assembly of unstructured oligomers of a new type. Whether EGCG disassembles preformed amyloid fibrils, however, remained unclear. Here, we show that EGCG has the ability to convert large, mature alpha-synuclein and amyloid-beta fibrils into smaller, amorphous protein aggregates that are nontoxic to mammalian cells. Mechanistic studies revealed that the compound directly binds to beta-sheet-rich aggregates and mediates the conformational change without their disassembly into monomers or small diffusible oligomers. These findings suggest that EGCG is a potent remodeling agent of mature amyloid fibrils.


Subject(s)
Amyloid Neuropathies/prevention & control , Amyloid beta-Peptides/metabolism , Amyloid/biosynthesis , Catechin/analogs & derivatives , Neuroprotective Agents/pharmacology , alpha-Synuclein/metabolism , Amyloid/drug effects , Amyloid Neuropathies/drug therapy , Animals , Blotting, Western , CHO Cells , Catechin/pharmacology , Chromatography, Affinity , Circular Dichroism , Cricetinae , Cricetulus , Escherichia coli , Humans , Microscopy, Atomic Force , Microscopy, Electron, Transmission , Microscopy, Fluorescence , PC12 Cells , Rats
5.
Nat Struct Mol Biol ; 15(6): 558-66, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18511942

ABSTRACT

The accumulation of beta-sheet-rich amyloid fibrils or aggregates is a complex, multistep process that is associated with cellular toxicity in a number of human protein misfolding disorders, including Parkinson's and Alzheimer's diseases. It involves the formation of various transient and intransient, on- and off-pathway aggregate species, whose structure, size and cellular toxicity are largely unclear. Here we demonstrate redirection of amyloid fibril formation through the action of a small molecule, resulting in off-pathway, highly stable oligomers. The polyphenol (-)-epigallocatechin gallate efficiently inhibits the fibrillogenesis of both alpha-synuclein and amyloid-beta by directly binding to the natively unfolded polypeptides and preventing their conversion into toxic, on-pathway aggregation intermediates. Instead of beta-sheet-rich amyloid, the formation of unstructured, nontoxic alpha-synuclein and amyloid-beta oligomers of a new type is promoted, suggesting a generic effect on aggregation pathways in neurodegenerative diseases.


Subject(s)
Amyloid Neuropathies/prevention & control , Amyloid/drug effects , Catechin/analogs & derivatives , Plaque, Amyloid/drug effects , Amyloid/chemistry , Amyloid Neuropathies/drug therapy , Amyloid beta-Peptides/chemistry , Catechin/chemistry , Catechin/pharmacology , Humans , Peptide Fragments/chemistry , Plaque, Amyloid/chemistry , Protein Binding , alpha-Synuclein/chemistry
6.
Internist (Berl) ; 45(10): 1177-81, 2004 Oct.
Article in German | MEDLINE | ID: mdl-15322706

ABSTRACT

A 34 year-old Turkish patient was admitted to hospital several times with the same symptoms of abdominal pain, fever up to 39.2 degrees C and vomiting. The diagnosis always was an acute attack of chronic pancreatitis. The inflammation scores in the blood were high and he had a moderate increase in pancreatic enzymes. He always got well in a few days on a strict diet and regime of analgesics. Taking these symptoms and his ethnic affiliation into consideration, differential diagnosis should include familial Mediterranean fever (FMF). Therapy with colchicine should be initiated even if genetic testing does not reveal the mutation characteristics for FMF. Immediate and consistent therapy helps to avoid amyloid nephropathy as the most dangerous complication of this disease.


Subject(s)
Abdominal Pain/diagnosis , Familial Mediterranean Fever/diagnosis , Familial Mediterranean Fever/therapy , Fever of Unknown Origin/diagnosis , Pancreatitis/diagnosis , Pancreatitis/therapy , Vomiting/diagnosis , Abdominal Pain/etiology , Abdominal Pain/therapy , Adult , Amyloid Neuropathies/etiology , Amyloid Neuropathies/prevention & control , Chronic Disease , Colchicine/therapeutic use , Diagnosis, Differential , Diet Therapy/methods , Familial Mediterranean Fever/complications , Fever of Unknown Origin/etiology , Fever of Unknown Origin/therapy , Genetic Predisposition to Disease/etiology , Humans , Male , Pancreatitis/complications , Recurrence , Vomiting/etiology , Vomiting/therapy
7.
Proc Natl Acad Sci U S A ; 91(18): 8368-72, 1994 Aug 30.
Article in English | MEDLINE | ID: mdl-8078889

ABSTRACT

The cardinal pathological features of Alzheimer disease are depositions of aggregated amyloid beta protein (A beta) in the brain and cerebrovasculature. However, the A beta is found in a soluble form in cerebrospinal fluid in healthy individuals and patients with Alzheimer disease. We postulate that sequestration of A beta precludes amyloid formation. Failure to sequester A beta in Alzheimer disease may result in amyloidosis. When we added A beta to cerebrospinal fluid of patients and controls it was rapidly sequestered into stable complexes with transthyretin. Complexes with apolipoprotein E, which has been shown to bind A beta in vitro, were not observed in cerebrospinal fluid. Additional in vitro studies showed that both purified transthyretin and apolipoprotein E prevent amyloid formation.


Subject(s)
Amyloid Neuropathies/prevention & control , Amyloid beta-Peptides/metabolism , Prealbumin/metabolism , Amino Acid Sequence , Computer Graphics , Humans , In Vitro Techniques , Models, Molecular , Molecular Sequence Data , Prealbumin/cerebrospinal fluid , Protein Binding
SELECTION OF CITATIONS
SEARCH DETAIL
...